The mainstream has seen a significant surge in CBD products since the Farm Bill’s passing in December 2018.
According to predictions made by BDS Analytics, a cannabis market research firm based in Boulder, CBD sales should surpass $20 billion by 2024.
The IPO of Tilray hit $300 on an intra-day, which is very remarkable for a CBD stock and set the company up for an impressive start.
By the time the year was coming to an end, TLRY stock prices had reduced 75% in value.
Hence, it’s reasonable if investors aren’t lining up to put money behind this company.
In a stock market that’s unpredictable, the CBD stock sector can be very risky and volatile.
The golden question is, how long will this last? The stocks in the cannabis industry don’t encourage bold predictions.
The financial support provided by the acquisition through Altria, a giant in the tobacco industry, has benefited CRON immensely.
Nevertheless, the ride hasn’t been easy for Cronos, and it’s counterparts.
In the report, Aphria was accused of acquiring assets for corporate insiders instead of its shareholders.
The news also led to other consequences, such as the dismissal of Vic Neufeld, the former CEO, and Cole Cacciavillani, the co-founder.
From the month of May to August, the stocks of the company reduced by 41% in value.
Make no mistake; the future shows tremendous growth potential for CBD products.
In light of the expected growth of the cannabis industry, investing in these seven CBD stocks could be a strategic step to position yourself for future gains.
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies.
are not responsible for each other’s services and products.